Background. The optimal dosing and the efficacy of rituximab for primary membranous nephropathy (PMN) has not been established. This multicentric prospective study evaluates the efficacy and safety of low-dose rituximab (RTX) therapy in patients with PMN in clinical practice. Methods. Thirty-four consecutive patients with PMN and nephrotic syndrome were included and received RTX (375 mg/ m
I N T R O D U C T I O N
Primary membranous nephropathy (PMN) is an autoimmune disease caused by autoantibodies directed against podocyte antigens such as phosholipase A2 receptor (PLA2R) [1, 2] and, less frequently, thrombospondin type-1 domain-containing 7A (THSD7A), a protein collocated with nephrin [3] , and with structural and biochemical features similar to PLA2R. PMN is typically a disease of adults and is characterized by the presence of nephrotic syndrome (NS) in 70-80% of patients. The natural course is variable. About 30% of patients with PMN undergo spontaneous remission [4] , but most patients with persisting NS may progress to end-stage renal disease within 10 years [5, 6] . The importance of proteinuria as a predictor of long-term outcome has been supported by a number of studies. Among the different variables, time-varying proteinuria (the instantaneous value at each time point) in the early course of MN is now considered to be the best metric to evaluate the prognostic effects of proteinuria over time [7] . Thus, an aetiologic treatment is recommended for patients with persistent NS and several therapeutic options are available. Among them, mid-term and long-term randomized trials demonstrated that a 6-month cyclical therapy alternating every other month of intravenous pulses of methylprednisolone plus oral prednisone with an alkylating agent proved to be superior to symptomatic therapy or to corticosteroids alone [8] [9] [10] [11] . Accordingly, such a therapy has been recommended as an initial treatment of PMN by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, while cyclosporine or tacrolimus is recommended in patients who do not tolerate or refuse alkylaying agents [12] . In recent years, a few observational studies have reported the possibility of obtaining remission using rituximab (RTX), a monoclonal antibody directed against the CD20 expressed on the 
surface of B cells [13] [14] [15] . However, head-to-head comparisons in randomized clinical trials are missing. Moreover, the optimal dosage of RTX in patients with PMN is still uncertain. Few investigators have reported good results with low-dose RTX [16, 17] , while the majority prefer to administer a standard dose of 375 mg/m 2 every week for 4 weeks associated or not with a second course at 6 months [14, 15] . Waiting for the results of controlled trials that compare the efficacy of RTX with other therapeutic approaches in PMN [18, 19] , further data about its use in a clinical practice setting may be helpful for clinicians.
In this prospective study, we report our experience using low-dose RTX in patients with PMN treated between 2010 and 2014 in four renal units of northern Italy.
M A T E R I A L S A N D M E T H O D S
Four renal units in northern Italy (Fondazione IRCCS Ca' Granda Ospedale Maggiore Milano, Ospedale San Carlo Milano, Ospedale A. Manzoni Lecco, Ospedale Sant' Anna Como) participated in this observational study. Given that the treatment with RTX is off-label for primary glomerulonephritis, in accordance with Italian law, every patient with PMN received authorization from the hospital authorities before being treated and signed an informed consent.
Patients with NS (see definitions) and biopsy-proven PMN who were followed for at least 1 year after receiving RTX as sole therapy between January 2010 and December 2014 were eligible for inclusion. Patients who were positive for hepatitis B antigen, hepatitis C virus antibodies, diabetes mellitus, malignancy, autoimmune disease, infections and/or exposure to toxic agents that could induce MN were excluded.
Methods
Anti-PLA2R antibody detection was performed using the commercial Human Embryonic Kidney (HEK)-293 transfected cell-based IIFT (PLA2R IIFT, Euroimmun), as previously described [20] . The system consists of glass slides containing two different biochips for each well, one coated with the PLA2R-1 c-DNA transfected cells (substrate, overexpressing the full-length human PLA2R1) and the other with 'mock' transfected HEK-293 cells as negative control (mock transfection is transfection without DNA, to control the potential effects of transfection reagent on the cells).
Briefly, serial sample dilutions from patients and controls were diluted in phosphate-buffered saline and incubated over the slide wells for 30 min at room temperature. After discarding and washing the unbound material, slides were overlaid with the FITC-conjugate goat anti-human IgG for further 30 min, then washed again and covered for evaluation with the ultraviolet-equipped microscope (Leica DM 1000, light source mercury vapour lamp, excitation filter 490 nm and emission filter 520 nm, 100 W, 40Â magnification).
The presence of fluorescent staining of the cytoplasm of the PLA2R transfected cells, partly including the cell membrane, was considered positive; negativity of anti-PLA2R was defined as the absence of detectable antibodies at serum dilution of 1/ 10. Antibody positivity was defined as positive staining at serum dilutions !1/10. In anti-PLA2R-positive patients, quantitative measurements were performed using different serum dilutions giving a semi-quantitative titre; confirmation was given by the negative pattern of the control biochip [20] .
Definitions
NS was defined as proteinuria >3.5 g/day and plasma albumin concentrations <3 g/dL. Complete response was proteinuria 0.5 g/day, normal or stable glomerular filtration rate (eGFR evaluated with the MDRD formula). Partial response was proteinuria <3.5 g/day with a reduction of proteinuria of at least 50% and stable renal function. No response was a <50% reduction of proteinuria or worsening of serum creatinine.
Therapeutic schedules
Treatment was decided by nephrologists and approved by patients after discussing the pros and cons of the suggested approaches. Eighteen patients received one dose and 16 received two doses of RTX. No patient received a supplemental dose of RTX at 6 months. Informed consent was signed by all patients.
All patients were submitted to the evaluation of CD19 þ lymphocytes before RTX infusion. RTX was administered intravenously at a dose of 375 mg/m 2 , under the supervision of a physician. Patients received standard premedication with antihistamine, paracetamol and intravenous methylprednisolone in some cases. Circulating CD19 þ lymphocytes were counted 1 and 2 weeks and 1 month after RTX.
Statistical analysis
Means and standard deviations together with medians and ranges were used as descriptive statistics. For continuous variables, the t-test was used for assessing any difference between the two groups, while the v 2 test was used for dichotomized variables.
R E S U L T S
Between 2010 and 2014, 44 consecutive patients with a diagnosis of PMN confirmed by renal biopsy were treated with RTX in the four renal units that participated in the study. Ten patients did not meet the criteria for inclusion and were excluded from the study: two because of non-nephrotic proteinuria, one because of a concomitant autoimmune disease and four because they had received RTX in association with prednisone (two patients) or cyclosporine (two patients). Three other patients were excluded because they had received both alkylating agents and RTX during the year of observation. The remaining 34 patients were included in this prospective, observational study.
The clinical and histological characteristics of these patients are reported in Table 1 . Most patients were males, and 71% were positive for anti-PLA2R antibodies. The median age at inclusion was 47.5 years (range 22-77) and the median time between the diagnosis of PMN and RTX therapy was 1.36 years (range 0.02-14.7). Fourteen patients (41%) had an eGFR <60 mL/min and the median proteinuria was 9.2 g/day (range 3.6-36.5).
All patients achieved complete depletion of circulating CD19 þ lymphocytes within 2 weeks after the first RTX infusion (data not shown).
Eighteen patients received one dose and 16 received two doses of RTX; the second dose was generally administered 2 weeks after the first one. At baseline, the only significant clinical difference between the two groups was a significantly higher proteinuria in patients who received two doses of RTX (proteinuria 8.8 6 5.7 versus 15 6 9 g/day; P ¼ 0.02).
RTX was the first-line therapy in 19 patients. The other 15 patients had previously received immunosuppressive therapy. Among them, 11 patients had been treated with cyclical therapy consisting of three intravenous methylprednisolone pulses (1 g each given every day) followed by oral methylprednisolone 0.4 mg/kg body weight per day for 27 days and then cyclophosphamide at a mean dose of 2.0 mg/kg body weight per day for 30 days. This schedule was repeated three times for a total of 6 months of therapy [8] [9] [10] [11] .
Nine of these 11 patients achieved response to cyclical therapy (6 complete, 3 partial response) and 2 were nonresponders. All nine responders showed a recurrence of NS a median of 27 months after the end of treatment and were enrolled in this study and received RTX. The remaining four patients had been treated with cyclical therapy followed by mycophenolate mofetil (n ¼ 2) and cyclosporine (n ¼ 2). None of them responded to these treatments.
Response at 12 months
The clinical outcomes at 3, 6 and 12 months after rituximab therapy are reported in Table 2 . Serum creatinine did not significantly change from baseline to 12 months. Proteinuria progressively decreased, the reduction becoming significant compared with baseline from the 6 month (11.9 6 8.2 versus 7.8 6 6.3 g/ day; P ¼ 0.02) and was maintained at 12 months (11.9 6 8.2 versus 6.5 6 7.9 g/day; P ¼ 0.007). From the third month, total serum protein (4.8 6 0.8 versus 5.6 6 0.9 g/dL; P ¼ 0.00) and serum albumin (2.4 6 0.6 versus 2.9 6 0.6 g/dL; P ¼ 0.001) significantly improved.
Three months after RTX infusion, 11 patients (32%) were in partial response. At 6 months, the number of patients in partial response was unchanged and, in addition, four other patients achieved a complete response. At 12 months, 5 patients (14.7%) Table 1 . Patients who achieved complete response had lower serum creatinine (1.12 6 0.48 versus 1.47 6 0.55 mg/dL; P ¼ ns), higher eGFR (83.5 6 31.3 versus 52.2 6 23.7; P ¼ 0.022) and lower proteinuria (8.28 6 5.82 versus 13.37 6 9.4 g/day; P ¼ ns) compared with non-responders.
Moreover, patients who achieved complete or partial remission had a statistically significant (although borderline) lower titre (reciprocal of dilution) of anti-PLA2R antibodies at baseline than patients who did not respond (163.1 6 129.8 versus 464.2 6 460.2; P ¼ 0.053).
At 12 months, the outcome of patients who received a single dose of RTX was comparable to that of the patients who received two doses (complete response 16.6 versus 12.5%, partial response 27.7 versus 31.2%, no response 55.5 versus 56%, respectively).
Complete remission was achieved in 21% of anti-PLA2R-positive patients versus none of the negative patients. Partial and no response occurred in 29 and 50% of anti-PLA2R-positive patients compared with 30 and 70% of negative patients.
Furthermore, at 12 months, 68% of patients treated with RTX as first-line therapy and 40% of those who received previous immunosuppressive treatments were non-responders. Complete and partial response in patients who received previous therapy were, respectively, 6.6 and 53.4% compared with 21.5 and 10.5% after first-line RTX therapy.
In the 15 patients treated with RTX as second-line therapy, we compared the response to RTX to that achieved with cyclical therapy (Table 3 ). The type of response to the two treatments was very similar. Patients who achieved response to cyclical therapy also responded to RTX, while those who did not respond to cyclical therapy did not show response to RTX.
Outcome after 12 months
Twenty-four of the 34 patients were followed for at least 18 months after RTX therapy (mean 23.9 6 18.6 months). In Table 4 , we compared the outcome at 12 months with that at the last observation in these patients. Two patients who did not respond at 12 months entered partial response, while two patients who responded at 12 months had a relapse of NS. At the last observation, the mean serum creatinine of the whole group was significantly higher than that at 12 months (1.6 6 0.8 versus 1.3 6 0.5 mg/dL; P ¼ 0.02). This was mainly due to an increase in serum creatinine in six non-responders. The mean proteinuria was not significantly different (5.1 6 6.8 versus 7.5 6 7.7 g/day; P ¼ 0.18).
Side effects
One patient developed atrial fibrillation during RTX infusion, another patient had bullous dermatitis 1 day after RTX. An infectious complication occurred in two patients: one had herpes zoster and the other one pneumonia. One patient had myocardial infarction 3 months after RTX infusion.
D I S C U S S I O N
In this prospective, observational study, we describe the outcome of 34 consecutive patients with PMN and NS who were treated with low-dose RTX between 2010 and 2014 in four Italian nephrology centres. Among these 34 patients admitted to the study, 56% had never received previous treatment while the remaining 44% had already received a treatment before RTX that led to either achieving remission followed by relapse of NS or was ineffective.
At 12 months, <50% of patients responded to RTX therapy and only 15% achieved complete response. Response occurred $6 months after RTX, similar to what was reported by Ruggenenti et al. [15] , who observed response after a median interval of 7.1 months after RTX. We found a much lower rate of complete and partial response in comparison with other reports [14, 15, 21, 22] . In a study including 100 patients with PMN, Ruggenenti et al. [15] reported the achievement of complete response in 27%, partial response in 38% and no response in 35% of patients over a median follow-up of 29 months. Total response at 12 months was achieved in 28 patients (82%) collected in eight French nephrology centres [23] .
The short-term follow-up may have precluded us from seeing a greater number of remissions. Indeed, in many cases, patients with PMN can enter remission after >2 years, independent of the type of treatment [6, 10, 14] . Beck et al. [21] found a rate of total response of 59% at 12 months in 35 patients treated with RTX. This rate increased to 88% when the followup was prolonged to 24 months. Fervenza et al. [14] treated 20 Table 4 . Comparison between the outcome at 12 months after RTX therapy with that at the last observation in 24 patients followed for a mean of 23.9 6 18.6 months patients with PMN with four weekly doses of RTX (375 mg/ m 2 ). The treatment was repeated at 6 months regardless of response. After a mean follow-up of 2 years, 4 patients were in complete and 12 in partial remission. When the follow-up of our patients was prolonged to 2 years, the results did not change substantially; two non-responders achieved partial response and two responders had a recurrence of NS.
Our unsatisfactory results may be attributed to the use of a lower dose of RTX compared with the majority of the published studies [14, 15, 23] . A patient in our series with severe NS, who did not respond to a single RTX infusion, subsequently had complete remission with a full course of RTX (375 mg/m 2 every week for 4 weeks). As a matter of fact, the optimal dosing of RTX for PMN has not yet been established. In previous studies, a number of different therapeutic schedules have been used, i.e. the standard protocol of lymphoma (375 mg/m 2 every week for 4 weeks) [15] alone or associated with a second course at 6 months [14] ; a short lymphoma course (375 mg/m 2 every week for 2 or 3 weeks); and the rheumatoid arthritis protocol (1 g twice a month) [23] . To the best of our knowledge, in only one study was a single dose of RTX of 375 mg/m 2 employed [16] . Twelve patients received a single dose of 375 mg/m 2 and their outcomes were compared with those of 24 matched patients treated with four weekly doses of 375 mg/m 2 . At 12 months, the proportion of non-responders was 33% in both groups. In spite of the use of the same dosage of RTX, the outcome of our patients was worse. A possible explanation for this discrepancy could be the fact that Cravedi et al. [16] administered a further RTX dose when more than 5 B cells/mm 3 were detected in the circulation. We did not check for the duration of B cell suppression, so we cannot rule out that, in some patients, the dose of RTX was insufficient to maintain depleted B cells. Notwithstanding, Fervenza et al. [14] found no relationship between the response and number of B cells in the blood.
We did not find differences in response between one or two infusions of RTX, although patients who received two doses of RTX had higher proteinuria at baseline. Finally, more than onethird of our patients had an eGFR <60 mL/min and the patients who achieved complete response had an eGFR significantly higher than that of non-responders. These results are in agreement with those of other reports that found higher rates of response to RTX in patients with better renal function and lower proteinuria at baseline [15] .
It was demonstrated that levels of anti-PLA2R may significantly influence the clinical response [24] [25] [26] [27] . Independent of the immunosuppressive therapy, patients who experienced remission of proteinuria after 12 months had significantly lower anti-PLA2R levels at baseline than non-responder patients [24, 25] . We measured the anti-PLA2R antibody titre in a semiquantitative way using indirect immunofluorescence (and not ELISA), since it was the only assay available when we started our work. However, it has been shown that the two assays correlate quite well [28] . Indeed, also in our cohort, patients with high titres of anti-PLA2R had a lower response rate, as previously shown by others [24, 25] . It is possible that, in our patients with high antibodies levels, additional RTX doses, independent from B cell depletion, would have led to more remissions. We cannot confirm the value of the serial evaluation of these antibodies in monitoring the clinical course of the disease [21] , as in our study the evaluation of anti-PLA2R was performed only at baseline.
Probably, one or more of these factors may account for the poor response to RTX in our series.
Of interest, in our cohort, patients who already responded to previous treatments then relapsed also responded to RTX, while patients who did not respond to previous treatments proved to be refractory to RTX. These data are in apparent contradiction with the results of Ruggenenti et al. [15] , who pointed out the possibility of achieving response with RTX even in patients who did not respond to previous treatments. Complete or partial response was achieved in 69% of 68 patients given RTX as firstline therapy compared with 56% of 32 patients who previously received immunosuppressive therapy [15] .
We observed a relapse of NS in 8% of patients who entered complete or partial remission within the second year. This rate is similar to that reported by a multicentre French study [23] and lower than the 30% observed in studies with longer followups [15] .
Similar to previous reports [14, 15] , RTX was well tolerated. Two cases of non-serious infection occurred and patients fully recovered without sequelae.
Our study has some limitations. It is an observational and not a controlled study, with a relatively short follow-up and a small number of patients enrolled. The dosage of anti-PLA2R was done only at baseline. The dosage of RTX is lower than that generally used in previous studies.
However, since negative results are seldom reported, the efficacy of RTX in PMN might be overestimated. This is one of the reasons why we think that our results should be accessible to the medical community.
In conclusion, these data show that low-dose RTX can obtain a response in a small number of patients with PMN. In most patients, the response was partial and only a minority entered complete remission. Patients with normal renal function, lower proteinuria, lower anti-PLA2R antibodies and those who responded to previous treatments were the most likely to achieve a response. On the basis of the comparison between data from the literature and ours, if RTX is to be used in patients with PMN, higher doses and longer treatments are needed to induce and maintain a response, particularly in patients with high titres of anti-PLA2R antibodies. The economic impact and potential long-term morbidity of such a treatment should be carefully evaluated in deciding the optimal treatment of patients with PMN and NS.
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